Left ventricular hypertrophy in the renal patient

Journal of the American Society of Nephrology

Volumn 12, Issue 5, 2001, Pages 1079-1084

  Middleton, R J ^a   Parfrey, P S ^a   Foley, R N ^a  

^a HOPE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CONTRACTILE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN;

ANEMIA; ARTICLE; CARDIOMYOPATHY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BIOPSY; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; HYPERTENSION; KIDNEY FAILURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; UREMIA;

EID: 0035028688     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Signalling pathways for cardiac hypertrophy and failure
2. Reduced capillary density in the myocardium of uremic rats - A stereological study
3. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia
4. Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: The effects of ramipril, nifedipine and moxonidine
5. Endothelin receptor antagonists influence cardiovascular morphology in uremic rats
6. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia
7. Effects of ACE inhibition and bradykinin antagonism on cardiovascular changes in uremic rats
8. Cardiac remodelling in experimental renal failure - An immunohistochemical study
9. Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging
10. Echocardiographic criteria for left ventricular hypertrophy: The Framingham heart study
11. The reliability and validity of echocardiographic assessment of left ventricular mass index in hemodialysis patients
12. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy
13. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension
14. The prognostic importance of left ventricular geometry in uremic cardiomyopathy
15. Left ventricular mass index in early renal disease. Impact of a decline in hemoglobin
16. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy
17. Accelerated atherosclerosis in prolonged maintenance hemodialysis
18. Uremic cardiomyopathy: An inadequate left ventricular hypertrophy
19. The long-term evolution of uremic cardiomyopathy
20. Outcome and risk factors for left ventricular disorders in chronic uremia
21. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease
22. The impact of anemia on cardiomyopathy, morbidity, and mortality in end stage renal disease
23. Anemia in hemodialysis patients: Variables affecting this outcome predictor
24. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - The experience of the Lombardy Dialysis Registry
25. Hematocrit level and associated mortality in hemodialysis patients
26. Hematocrit levels and hospitalization risks in hemodialysis patients
27. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis
28. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin
29. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients
30. rHuEPO treatment improves brain and cognitive function of anemic dialysis patients
31. Exercise in hemodialysis patients after treatment with recombinant human erythropoietin
32. Improved physical performance after treatment of renal anemia with recombinant human erythropoietin
33. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin
34. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin
35. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
36. The impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease
37. Inadequate diagnosis and therapy of arterial hypertension as causes of left ventricular hypertrophy in uremic dialysis patients
38. Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs
39. Clinical and biochemical correlates of starting "daily" hemodialysis
40. In search of ideal hemodialysis: Is prolonged frequent dialysis the answer?
41. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects
42. Angiotensin-converting enzyme gene polymorphism and reversibility of uremic left ventricular hypertrophy following long-term antihypertensive therapy
43. Cardiac hypertrophy, aortic compliance, peripheral resistance and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade
44. Impact of renal transplantation on uremic cardiomyopathy
45. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure
46. Myocardial calcification and cardiac dysfunction in chronic renal failure
47. Association of serum phosphorus and calcium-phosphate product with mortality in chronic hemodialysis patients: A national study
48. Cases and observations, illustrative of renal disease accompanied with the secretion of albuminous urine